CDC Study Shows Effectiveness Of RSV Immunization For Infants

Early data from the New Vaccine Surveillance Network show nirsevimab is 90% effective in preventing infants from being hospitalized with RSV

Health & Lifestyle
559

Listen to article (english)

Translate to Spanish or other 102 languages!

The current RSV season is the first time nirsevimab was available to protect infants from severe RSV, so the data released today are the first United States estimates of nirsevimab effectiveness in protecting infants against RSV-related hospitalization in their first season of potential exposure to the virus. Image for illustration purposes
The current RSV season is the first time nirsevimab was available to protect infants from severe RSV, so the data released today are the first United States estimates of nirsevimab effectiveness in protecting infants against RSV-related hospitalization in their first season of potential exposure to the virus. Image for illustration purposes

Mega Doctor News

- Advertisement -

New data released today in CDC’s MMWR show that nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV). RSV is the leading cause of hospitalization among infants in the United States, and this finding supports CDC’s recommendation to protect infants in their first RSV season by giving the infant nirsevimab if the mother did not receive the maternal RSV vaccine during pregnancy.

The current RSV season is the first time nirsevimab was available to protect infants from severe RSV, so the data released today are the first United States estimates of nirsevimab effectiveness in protecting infants against RSV-related hospitalization in their first season of potential exposure to the virus.

The study looked at 699 infants from October 2023 through February 2024 using early data from CDC’s New Vaccine Surveillance Network (NVSN), a population-based surveillance platform that monitors pediatric respiratory viruses to assess immunization effectiveness. Results show that nirsevimab was 90% effective at preventing RSV-associated hospitalization in infants during their first RSV season. These results reflect a shorter surveillance period due to the introduction of this new product in August 2023. Nirsevimab effectiveness may be lower over a full RSV season (October through March in most of the United States). With increasing availability of nirsevimab in future RSV seasons, CDC will assess its effectiveness over an entire season.

- Advertisement -

RSV prevention products remain our single most important tool to protect infants from RSV. Healthcare providers should recommend either:

  • Infant immunization withnirsevimab for all infants who are younger than 8 months, born during or entering their first RSV season, if their mother did not receive the maternal RSV vaccine; or
  • Maternal RSV vaccination – giving the RSV vaccine (Abrysvo) to pregnant people during weeks 32 through 36 of pregnancy if that period falls between September and January in most of the United States.

CDC continues to monitor the safety and effectiveness of nirsevimab and maternal RSV vaccines.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Heart Disease Doesn’t Have to Keep You from Donating Blood
Next article
Primary Care Scarcity Linked to More Surgical Emergencies & Problems

More Articles

New Noninvasive Tech Tracks Infant Vital Signs Without Wires

In the neonatal intensive care unit, the most fragile patients in medicine are often the most heavily wired. Premature babies, some weighing less than a pound, can be tethered to a tangle of cables, monitors, and sensors. Each blood draw to check sugar levels or electrolytes means another needle, another bandage, another moment of stress for an infant whose skin is still forming.

The Truth About Hot Dogs and Your Health

July is National Hot Dog Month. Reports show Americans eat roughly 20 billion hot dogs every year. While they’re okay to have on occasion, they shouldn’t be a regular part of your diet.

Study Links Type 2 Diabetes to Higher Risk of Hearing Loss

Diabetes is well known to increase the risk of complications throughout the body, potentially affecting the eyes, kidneys, and nerves. 

Researchers Unlock New Way to Help Fight Skin Cancer

Researchers at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center have identified a potential solution. In a new study published in the Journal of Clinical Investigation, researchers have found that by inhibiting a problematic protein, the immune system can better fight off melanoma, decreasing tumor growth and bolstering the body’s immune cells.
- Advertisement -